Retrospective Chart Review Study of Korlym for the Treatment of ACTH Independent Cushing's Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

24 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-10-31

Study Completion Date

2017-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Chart review study to collect patient data from medical charts of patients who have been treated with Korlym® for the treatment of ACTH independent adrenal Cushing's Syndrome.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Retrospective Chart Review Study of Pediatric Patients Treated With Korlym for Cushing Syndrome

NCT03379363

Hypercortisolism Cushing Syndrome

TERMINATED

Study to Evaluate CORT125134 in Participants With Cushing's Syndrome

NCT02804750

Cushing's Syndrome

COMPLETED PHASE2

Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome

NCT03604198

Cushing Syndrome

ACTIVE_NOT_RECRUITING PHASE2

A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome

NCT03697109

Cushing Syndrome

COMPLETED PHASE3

Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing s Disease

NCT04339751

Cushing's Disease

WITHDRAWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A retrospective, multi-center, chart review study to collect patient data from medical charts of patients who have been treated with Korlym® for the treatment of ACTH independent adrenal Cushing's Syndrome. Treatment with Korlym® will be a minimum 3 months in duration with follow-up of a minimum 3 months. Only sites that have been identified to have patients appropriate for this protocol will be invited to participate.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cushing's Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No intervention

No treatment (intervention) was administered.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosed with ACTH independent endogenous Cushing's Syndrome
* Available adrenal imaging prior to being treated with Korlym®
* Treated with Korlym® and followed for at least 3 months (follow-up data should be available)